drugset / Trial / NCT06680505
Safety and Efficacy Study of YZJ-1139 in Primary Chronic Insomnia Disorder
RandomizedParallel-groupDouble-blindTreatment
Summary
The main purpose of this study is to evaluate the efficacy and safety of YZJ-1139 in the short-term treatment of primary chronic insomnia, explore the optimal effective dose, and provide the basis for phase III clinical trials
Timeline
- Start
- 2019-08-04
- Primary completion
- 2020-09-30
- Completion
- 2021-03-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FAZAMOREXANT | Small molecule | 10 mg | — |
| Subject | FAZAMOREXANT | Small molecule | 20 mg | — |
| Subject | FAZAMOREXANT | Small molecule | 40 mg | — |
| Subject | FAZAMOREXANT | Small molecule | 60 mg | — |